Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 11/20 | 0.79 |
| ▸ | FOLR1 | P15328 | 2/20 | 0.69 |
| ▸ | SLC19A1 | P41440 | 2/20 | 0.69 |
| ▸ | SLC46A1 | Q96NT5 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | TLR4 | O00206 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | TYMS | P04818 | 1/20 | 0.69 |
| ▸ | GLA | P06280 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.69 |
| ▸ | GART | P22102 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL864864 | 1.00 | DHFR (0.79) | DHFRFOLR1SLC19A1SLC46A1KDM4E | |
| SCHEMBL6907145 | 0.92 | DHFR (0.67) | DHFRFOLR1SLC19A1SLC46A1KDM4E | |
| Aminopterin SCHEMBL29398079 | 0.91 | DHFR (0.76) | DHFRFOLR1SLC19A1SLC46A1KDM4E | |
| Aminopterin SCHEMBL9514067 | 0.91 | DHFR (0.76) | DHFRFOLR1SLC19A1SLC46A1KDM4E | |
| Aminopterin SCHEMBL8887 | 0.91 | DHFR (0.76) | DHFRFOLR1SLC19A1SLC46A1KDM4E | |
| Aminopterin SCHEMBL29443569 | 0.91 | DHFR (0.76) | DHFRFOLR1SLC19A1SLC46A1KDM4E | |
| Aminopterin SCHEMBL8161477 | 0.91 | DHFR (0.76) | DHFRFOLR1SLC19A1SLC46A1KDM4E | |
| Aminopterin SCHEMBL1626034 | 0.91 | DHFR (0.76) | DHFRFOLR1SLC19A1SLC46A1KDM4E | |
| Aminopterin SCHEMBL20769794 | 0.91 | DHFR (0.76) | DHFRFOLR1SLC19A1SLC46A1KDM4E | |
| Aminopterin SCHEMBL23581239 | 0.90 | DHFR (0.75) | DHFRFOLR1SLC19A1SLC46A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120136335-A1 | FOCAL MEDICATION TITRATION SYSTEM | HOBBS JONATHAN P (US) | 2012-05-31 | — | — | US | claimed |
| EP-1991586-B1 | CHIMERIC CONSTRUCTS BETWEEN CANCER-HOMING PEPTIDES AND CELL-PENETRATING PEPTIDES COUPLED TO ANTICANCER DRUGS AND/OR DIAGNOSTIC AGENT/AGENTS | CEPEP III AB (SE) | 2011-01-12 | — | — | EP | claimed |
| EP-2547367-A1 | SYSTEM FOR IMPROVED DELIVERY OF GENE MODULATING COMPOUNDS | GE Healthcare Bio-Sciences AB (SE) | 2013-01-23 | — | — | EP | disclosed |
| US-20130011448-A1 | SYSTEM FOR IMPROVED DELIVERY OF GENE MODULATING COMPOUNDS | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2013-01-10 | — | — | US | disclosed |
| WO-2011115555-A1 | SYSTEM FOR IMPROVED DELIVERY OF GENE MODULATING COMPOUNDS | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2011-09-22 | — | — | WO | disclosed |
| EP-1991586-B1 | CHIMERIC CONSTRUCTS BETWEEN CANCER-HOMING PEPTIDES AND CELL-PENETRATING PEPTIDES COUPLED TO ANTICANCER DRUGS AND/OR DIAGNOSTIC AGENT/AGENTS | CEPEP III AB (SE) | 2011-01-12 | — | — | EP | disclosed |
| US-20100279918-A1 | Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130011448-A1 | SYSTEM FOR IMPROVED DELIVERY OF GENE MODULATING COMPOUNDS | PHAX, ABCB1, BCR | DHFR 450/4885FOLR1 430/4885SLC19A1 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.